121 results about "Coagulation system" patented technology

Aspects of the present disclosure include an attachable power and control system to supply energy to electrodes of a wiping electrode coagulation system of a surgical device. A surgical device includes electrodes at an end of effector to aide in sealing during various surgical procedures. During the procedure, the surgeon may wipe the surgical site with the end effector, causing the electrodes to touch the fractured area. Electrosurgical energy may be applied to the electrodes during the wiping, causing coagulation of smaller vessels. The attachable power and control system may be configured to slide over the shaft of the surgical device. The power and control system also may be configured to supply power to the electrodes and to control when energy is applied to the electrodes, based in part, for example, on measuring a distance or angle of the opening of the jaws at the end effector.

Disclosed herein are wound dressings comprising fibrinogen and at least one procoagulant such as propyl gallate in a therapeutic amount. Also disclosed are methods of treating wounds, increasing an amount of or rate of coagulation of blood from a wound, increasing an amount of or rate of clot formation over a wound, increasing blood platelet counts, activating a coagulation system, increasing the plasma concentration of fibrinogen, and decreasing the activated partial thromboplastin time. Also disclosed are an arterial bleeding model and methods of studying arterial bleeding.

Provided is a standalone integrated water treatment system for a distributed water supply. A filter input receives water to be treated. A coagulation system is in operative connection with the filter input, wherein the water which has been filtered is subjected to a coagulation process performed by the coagulation system to create pin floc from suspensions in the water. A maturation buffer tank is in operative connection with the coagulation system, wherein floc is aggregated in size within the water. A spiral separator is in operative connection with the maturation buffer tank, and the water is separated into two water streams, a first stream of water having most of the floc removed, and a second stream of water which includes a concentrated amount of the floc. An optional filtration system is in operative connection with the spiral separator and is configured to receive the first stream of water and to perform a filtration operation on the first stream of water. A sterilization system is in operative connection with the optional filtration system and is configured to perform a sterilization operation on the first stream of water. The water is then output from the sterilization system as potable water.

The present invention provides novel compounds of formula 1a,

novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTP alpha, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

An electromagnetic energy supply system for supplying electromagnetic energy signals to an applicator for applying the electromagnetic energy signals to tissue for heating such tissue can supply electromagnetic energy signals of at least one selected frequency of a plurality of frequencies available for selection. The system includes a plurality of individual electromagnetic signal generators each adapted to generate signals of a particular frequency, such as two microwave energy signal generators with one operating at 915 MHz and one operating at 1450 MHz. A system controller coordinates operation of the generators. Each generator is connected to connectors for connecting an applicator or array of applicators for applying the selected frequency electromagnetic energy signals to the tissue to be heated. A power splitting circuit can provide multiple connectors tuned for one or for more than one applicator to be connected. The system can provide a treatment using a single selected frequency, a plurality of selected frequencies simultaneously, or can switch between selected frequencies.

A system and process for continuously and immediately removing contaminants from wastewater and treating wastewater, where the wastewater is treated to supply fluid that can be reused in the cleaning system or discharged safely into the environment is disclosed. The system and method comprises one or more pumping means for circulating and recirculating fluids captured or collected by the system to one or more of the processes in the system, such as wash water applications or further treatment cycles. According to one embodiment, the wastewater is transported through purification sections of the device. Depending on the system used, these sections could include several of the following: pretreatment to remove debris and certain heavy solids; treatment by methods such as a conductivity solution injection system and/or electrolytic coagulation system, a polymer injection system, and a inline mixer for mixing the polymer in the wastewater stream; and an ozone treatment system. In a preferred embodiment, each of the treatment sections are contained within an enclosure cabinet that includes a controller and feed containers for conductivity fluid and polymers.

The invention concerns novel coagulation factor VII variants, wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs;

with the proviso that the variant is not FVII(Ala305).

The invention further concerns nucleic acids encoding the Factor VII variants; vectors and cells comprising the nucleic acid; methods for producing the variants; pharmaceutical compositions comprising a Factor VII variant wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs; use of the variants for producing a medicament for treatment or prophylaxis of bleeding disorders or enhancement of the coagulation system; and methods of treatment.

A coagulation system for the coagulation of organic tissue includes a laser configured to emit a working beam; an interrupter configured to at least partially interrupt the working beam; a controller configured to activate the interrupter; and a detector configured to detect a signal corresponding to a degree of coagulation or alteration of the tissue and to transmit a detection of the signal to the controller, the detector including a dimension meter.

The invention relates to a method for preparing a liquid porcellanite activating partial thromboplastin (APTT) reagent. The reagent is mainly used for monitoring coagulation factor deficiency of endogenous coagulation systems and carrying out screening test of related inhibitors, and used for detecting coagulation factors, heparin anticoagulation treatment and lupus anticoagulation substances as the current main means. Taking porcellanite as an activating agent, the method improves the sensitivity to the coagulation factors; a novel stable system solves the problem of keeping the stability of the reagent at a liquid state; and the method has the advantages of high sensitivity, convenient use, small experimental error, strong stability, good compatibility, low cost and the like.

An improved method of administration of an aptamer and antidote system to regulate blood coagulation in a host is provided based on weight adjusted or body mass index-adjusted dosing of the components of the system to provide a desired pharmacodynamic response. In addition, a method of reversing activity of the aptamer to a desired extent is provided where an antidote dose is based solely on its relationship to the aptamer dose.

The invention discloses a blood purification membrane with an anticoagulant property and a preparation method thereof. The blood purification membrane comprises a matrix, a polydopamine layer attachedto the surface of the substrate, argatroban grafted on the polydopamine layer and glutathione. The whole surface modification process is simple in experimental conditions, has strong controllability,and is economical and environmentally-friendly; the high-efficiency anti-coagulation on the local part of a material is realized; the blood coagulation system of a body is not affected; the blood compatibility is significantly improved; and the grafted anticoagulant drug argatroban has no antigenicity and does not cause heparin-induced thrombocytopenia.

There is provided a blood coagulation system analyzer, including a measurement section and an analysis section. The measurement section measures a time change of impedance of a blood sample, which is obtainable by applying an alternating electric field to the blood sample. The analysis section extracts a parameter indicating the characteristics of the impedance from the measured data of the time change of the impedance. Furthermore, the analysis section analyzes a degree of enhancement of blood coagulation on the basis of a comparison of the extracted parameter with at least one reference value which defines the criteria of the enhancement of blood coagulation.

The invention discloses a sewage treatment device for a large-scale sewage treatment station. The sewage treatment device comprises a filtering device, a regulating hydrolysis tank, a grade-A biochemical tank, a grade-O biochemical tank, a precipitation tank, an improved coagulation system, a disinfection tank, a sludge thickening tank, oxygenation equipment and a gas stripping device, wherein the filtering device, the regulating hydrolysis tank, the grade-A biochemical tank, the grade-O biochemical tank, the precipitation tank, the improved coagulation system and the disinfection tank are connected with one another in sequence from front to back; the gas stripping device is a pulse gas stripping device which is used for stripping one part of sludge precipitated in the precipitation tank into the sludge thickening tank, and the other part of the sludge precipitated in the precipitation tank into the grade-A biochemical tank; the grade-O biochemical tank is provided with the oxygenation equipment which is a centrifugal blower. The invention also provides a sewage treatment method for the large-scale sewage treatment station. The sewage treatment device disclosed by the invention has the advantages of being full in filtration and high in treatment efficiency of precipitated sludge, saving the floor area, and having an integrated function of regulation and decomposition.

An ultrasonic dissection and coagulation system for surgical use is provided. The system includes an ultrasonic instrument, a control module, and a remote actuator. The ultrasonic instrument has a housing and an elongated body portion extending from the housing. An ultrasonic transducer supported within the housing is operatively connected to a cutting jaw by a vibration coupler. The vibration coupler conducts high frequency vibration from the ultrasonic transducer to the cutting jaw. The cutting jaw has a blade surface which is curved downwardly and outwardly in the distal direction with respect to the longitudinal axis of the elongated body portion along its length such that an angle defined by a line drawn tangent to the blade surface and the longitudinal axis of the elongated body portion varies between 5 degrees and 75 degrees. A clamp member having a tissue contact surface is positioned adjacent to the cutting jaw and is movable from an open position in which the tissue contact surface is spaced form the blade surface to a clamped position in which the tissue contact surface is in close juxtaposed alignment with the blade surface to clamp tissue therebetween. The clamp member and the curved cutting jaw combine to enhance contact between tissue and the blade surface of the cutting jaw during cutting. Further, the continuously varying angle of the blade surface with respect to the longitudinal axis of the elongated body portion facilitates selective user control over the application of force on tissue during a cutting or dissecting procedure.